Semaxanib

DB06436InvestigationalSmall molecule

Investigated for use/treatment in colorectal cancer and lung cancer.

Mechanism: Pharmacologically active on Aryl hydrocarbon receptor, Vascular endothelial growth factor receptor, and Platelet-derived growth factor receptor beta
Curator reviewed
Primary indication: Investigated for use/treatment in colorectal cancer and lung cancer.Curator reviewed
Formula / weight: C₁₅H₁₄N₂O · 238.2845 g/mol (avg)
Code names: NSC-696819 · SU005416 · SU-5416

Resolves to

Compound

Structure

InChIKeyWUWDLXZGHZSWQZ-WQLSENKSSA-NSMILESCC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12

Targets

What you can answer from here — as of June 15, 2026

10Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

48Drug interactionsStructured to mechanism, not free text

28Clinical trialsPhase, status and sponsor resolved per trial

33+ReferencesStructured and connected to the statements they support

Which drugs share a target with Semaxanib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.